甲状腺癌分子发病机制研究进展

doi:10.3881/j.issn.1000-503X.2013.04.005

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2013, Vol. 35 ›› Issue (4): 382-385.doi: 10.3881/j.issn.1000-503X.2013.04.005

Previous Articles Next Articles

Research Advances in Molecular Pathogenesis of Thyroid Cancer

Aleha·Maotihan,MENG Qing-bin,YU Jian-chun,KANG Wei-ming,CAO Zhan-jiang,TIAN Shu-bo

Department of General Surgery,PUMC Hospital,CAMS and PUMC,Beijing 100730,China

Received:2013-07-03 Online:2013-08-30 Published:2013-08-30
Contact: YU Jian-chun Tel:01069152213,E-mail:yu-jch@163.com E-mail:yu-jch@163.com
Supported by:
Supported by the Ministry of Health Industry Special Scientific Research Project(201202012)

Abstract

Abstract: Thyroid cancer is the one of the most common endocrine tumors.The biological behaviors and prognoses of the thyroid cancer of different histological types remarkably differ.The highly invasive thyroid cancer responds poorly to traditional therapies.Recent research advances in the molecular mechanisms of the pathogenesis of thyroid cancer have revealed the roles of many genetic and epigenetic variations such as gene mutation,abnormal gene amplification,and abnormal gene methylation in the development of thyroid cancer,which provides new insights in the molecular diagnosis,prognosis,and target therapy of the thyroid cancer.

Key words: thyroid cancer, molecular mechanism, molecular target treatment

Aleha·Maotihan, MENG Qing-bin, YU Jian-chun, KANG Wei-ming, CAO Zhan-jiang, TIAN Shu-bo. Research Advances in Molecular Pathogenesis of Thyroid Cancer[J].Acta Academiae Medicinae Sinica, 2013, 35(4): 382-385.

References 33

[1]	Kilfoy BA,Zheng T,Holford TR,et al.International patterns and trends in thyroid cancer incidence,1973-2002[J] .Cancer Causes Control,2009,20(5):525-531.
[2]	Chen W,Zheng R,Zhang S,et al.Report of incidence and mortality in China cancer registries,2009[J] .Chin J Cancer Res,2013,25(1):10-21.
[3]	Tuttle RM,Ball DW,Byrd D,et al.Thyroid carcinoma[J] .J Natl Compr Canc Netw,2010,8(11):1228-1274.
[4]	Wreesmann VB,Singh B.Clinical impact of molecular analysis on thyroid cancer management[J] .Surg Oncol Clin N Am,2008,17(1):1-35,vii.
[5]	Fassnacht M,Kreissl MC,Weismann D,et al.New targets and therapeutic approaches for endocrine malignancies[J] .Pharmacol Ther,2009,123(1):117-141.
[6]	Catalano MG,Fortunati N,Boccuzzi G.Epigenetics modifications and therapeutic prospects in human thyroid cancer[J] .Front Endocrinol(Lausanne),2012,3:40.
[7]	Fugazzola L,De Leo S,Perrino M.The optimal range of RET mutations to be tested:European comments to the guidelines of the American Thyroid Association[J] .Thyroid Res,2013,6(Suppl 1):S8.
[8]	Xing M,Westra WH,Tufano RP,et al.BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer[J] .J Clin Endocrinol Metab,2005,90(12):6373-6379.
[9]	Lim JY,Hong SW,Lee YS,et al.Clinicopathologic implications of the BRAFV600E mutation in papillary thyroid cancer;a subgroup analysis of 3130 cases in a single center[J] .Thyroid,2013,http://online.liebertpub.com/doi/abs/10.1089/thy.2013.0036.
[10]	Li C,Lee KC,Schneider EB,et al.BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer:a meta-analysis[J] .J Clin Endocrinol Metab,2012,97(12):4559-4570.
[11]	Lupi C,Giannini R,Ugolini C,et al.Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma[J] .J Clin Endocrinol Metab,2007,92(11):4085-4090.
[12]	Elisei R,Viola D,Torregrossa L,et al.The BRAF(V600E)mutation is an independent,poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma:single-institution results from a large cohort study[J] .J Clin Endocrinol Metab,2012,97(12):4390-4398.
[13]	Xing M,Alzahrani AS,Carson KA,et al.Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer[J] .JAMA,2013,309(14):1493-1501.
[14]	Elisei R,Ugolini C,Viola D,et al.BRAF(V600E)mutation and outcome of patients with papillary thyroid carcinoma:a 15-year median follow-up study[J] .J Clin Endocrinol Metab,2008,93(10):3943-3949.
[15]	Fernandez IJ,Piccin O,Sciascia S,et al.Clinical significance of BRAF mutation in thyroid papillary cancer[J] .Otolaryngol Head Neck Surg,2013,148(6):919-925.
[16]	Knauf JA,Ma X,Smith EP,et al.Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation[J] .Cancer Res,2005,65(10):4238-4245.
[17]	Kim K,Cabanillas M,Lazar AJ,et al.Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring V600EBRAF mutation[J] .Thyroid,2013,http://online.liebertpub.com/doi/abs/10.1089/thy.2013.0057.
[18]	Feng C,Gao Y,Wang C,et al.Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer[J] .J Clin Endocrinol Metab,2013,http://jcem.endojournals.org/content/early/2013/07/10/jc.2012-4258.long.
[19]	Xing M.Molecular pathogenesis and mechanisms of thyroid cancer[J] .Nat Rev Cancer,2013,13(3):184-199.
[20]	Abubaker J,Jehan Z,Bavi P,et al.Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population[J] .J Clin Endocrinol Metab,2008,93(2):611-618.
[21]	Liu Z,Hou P ,Ji M,et al.Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers[J] .J Clin Endocrinol Metab,2008,93(8):3106-3116.
[22]	Miller KA,Yeager N,Baker K,et al.Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo[J] .Cancer Res,2009,69(8):3689-3694.
[23]	Gustafson S,Zbuk KM,Scacheri C,et al.Cowden syndrome[J] .Semin Oncol,2007,34(5):428-434.
[24]	Liu X,Bishop J,Shan Y,et al.Highly prevalent TERT promoter mutations in aggressive thyroid cancers[J] .Endocr Relat Cancer,2013,20(4):603-610.
[25]	Garcia-Rostan G,Tallini G,Herrero A,et al.Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma[J] .Cancer Res,1999,59(8):1811-1815.
[26]	Xing JC,Tufano RP,Murugan AK,et al.Single nucleotide polymorphism rs17849071 G/T in the PIK3CA gene is inversely associated with follicular thyroid cancer and PIK3CA amplification[J] .PLoS One,2012,7(11):e49192.
[27]	Liu Y,Cope L,Sun W,et al.DNA copy number variations characterize benign and malignant thyroid tumors[J] .J Clin Endocrinol Metab,2013,98(3):E558-E566.
[28]	Wu G,Mambo E,Guo Z,et al.Uncommon mutation,but common amplifications,of the PIK3CA gene in thyroid tumors[J] .J Clin Endocrinol Metab,2005,90(8):4688-4693.
[29]	Romei C,Elisei R.RET/PTC Translocations and clinico-pathological features in human papillary thyroid carcinoma[J] .Front Endocrinol(Lausanne),2012,3:54.doi:10.3389/fendo.2012.00054.
[30]	Fusco A,Grieco M,Santoro M,et al.A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases[J] .Nature,1987,328(6126):170-172.
[31]	Hieber L,Huber R,Bauer V,et al.Chromosomal rearrangements in post-Chernobyl papillary thyroid carcinomas:evaluation by spectral karyotyping and automated interphase FISH[J] .J Biomed Biotechnol,2011,http://www.hindawi.com/journals/bmri/2011/693691/.
[32]	Hu S,Liu D,Tufano RP,et al.Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer[J] .Int J Cancer,2006,119(10):2322-2329.
[33]	Rodriguez-Rodero S,Fernandez AF,Fernandez-Morera JL,et al.DNA methylation signatures identify biologically distinct thyroid cancer subtypes[J] .J Clin Endocrinol Metab,2013,98(7):2811-2821.

Acta Academiae Medicinae Sinica

Home

About Journal

Current Issue

Archive

Search

Contact Us

中文

Research Advances in Molecular Pathogenesis of Thyroid Cancer

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 33

Related Articles 15

Metrics

Recommended 10

[1]	LIU Jia,WANG Ying,ZHANG Bo. Advances in Diagnosis and Treatment of Thyroid Cancer in Children and Adolescents [J]. Acta Academiae Medicinae Sinica, 2018, 40(6): 838-842.
[2]	Ruyu LIU, Bo ZHANG. Role of Ultrasound in the Management of Thyroid Nodules and Thyroid Cancer [J]. Acta Academiae Medicinae Sinica, 2017, 39(3): 445-450.
[3]	Yan ZHANG, Yukun LUO, Mingbo ZHANG, Ming YANG, Ying ZHANG, Junlai LI, Jie TANG. Value of Contrast-enhanced Ultrasound and Conventional Ultrasound in the Diagnosis of Papillary Thyroid Carcinoma with Cervical Lymph Node Metastases [J]. Acta Academiae Medicinae Sinica, 2017, 39(2): 177-182.
[4]	Cong-xin LI, Min HOU, Chao REN, Yan-song LIN. Serial Thyroglobulin Variation Trend Shortly after Radioiodine Therapy in Poorly to Moderately Differentiated Recurrent Thyroid Cancer [J]. Acta Academiae Medicinae Sinica, 2016, 38(3): 351-355.
[5]	Min HOU, Teng ZHAO, Xue YANG, Jiao LI, Hui LI, Yan-song LIN. Response to ¹³¹I Therapy in Non-metastatic Differentiated Thyroid Cancer Patients with Preablative Stimulated Thyroglobulin above 10 ng/ml [J]. Acta Academiae Medicinae Sinica, 2016, 38(1): 83-87.
[6]	Xin-feng LIU, Jiao LI, Teng ZHAO, Min HOU, Hui LI, Jun LIANG, Yan-song LIN. Clinical Outcome of ¹³¹I Therapy in Differentiated Thyroid Cancer with Preablative Thyroglobulin below 10 ng/ml [J]. Acta Academiae Medicinae Sinica, 2016, 38(1): 88-92.
[7]	Xian-zhong LIU, Li-ting ZHANG, Wei-quan TONG, Shuai WANG, Zhi-bo XU, Fang CHEN. Research Advances in Molecular Mechanisms of the Invasion and Metastasis of Lung Cancer [J]. Acta Academiae Medicinae Sinica, 2016, 38(1): 108-112.
[8]	Hui CONG, Hui LI, Jun LIANG, Ke YANG, Teng ZHAO, Wen-sheng QIU, Yan-song LIN. Effect of Selenious Yeast Tablets on the Thyroglobulin Antibody Level in Thyroglobulin Antibody-positive Patients with Differentiated Thyroid Cancer [J]. Acta Academiae Medicinae Sinica, 2015, 37(5): 591-595.
[9]	Yan ZHANG, Yu-kun LUO, Jie TANG, Min LI, Zhi-li WANG, Quan WEN. Clinical Value of Ultrasonography in Diagnosing Diffuse Thyroid Diseases Accompanied with Suspicious Nodules [J]. Acta Academiae Medicinae Sinica, 2015, 37(3): 290-293.
[10]	Teng ZHAO, Jun LIANG, Tian-jun LI, Cong-xin LI, Hui CONG, Ke YANG, Fang LI, Yan-song LIN. Relationship between Variation of Pre-ablation Stimulated Thyroglobulin and Distant Metastasis in Patients with Differentiated Thyroid Cancer [J]. Acta Academiae Medicinae Sinica, 2015, 37(3): 315-319.
[11]	Hui CONG, Jun LIANG, Fang LI, Wen-sheng QIU, Yan-song LIN. Changes in Thyroglobulin Antibodies after Treatment of Differentiated Thyroid Cancer and Its Influencing Factors [J]. Acta Academiae Medicinae Sinica, 2015, 37(1): 61-65.
[12]	HAN Ting, LIANG Jun, MENG Chao, YANG Ke, LI Xiao-yi, LIN Yan-song. Correlations between Cellular Immunity and Invasiveness in Differentiated Thyroid Cancer [J]. Acta Academiae Medicinae Sinica, 2014, 36(1): 42-46.
[13]	KANG Wei-ming, ZHU Chang-zhen, TIAN Shu-bo, YU Jian-chun. Surgical Therapy of Thyroid Cancer [J]. Acta Academiae Medicinae Sinica, 2013, 35(4): 373-377.
[14]	MENG Chao, GAO Jie, LIANG Jun, LIANG Zhi-yong, LIN Yan-song. Invasive Properties of Papillary Thyroid Cancer with Concurrent BRAF^V600E Mutationand Rearranged during Transfection Proto-oncogene Protein Expression [J]. Acta Academiae Medicinae Sinica, 2013, 35(1): 64-68.
[15]	LI Tian-jun, LIN Yan-song, LIANG Jun, LI Fang. Time to Disappearance of Thyroglobulin Antibodies and Influencing Factors in Patients with Papillary Thyroid Carcinoma [J]. Acta Academiae Medicinae Sinica, 2012, 34(3): 258-261.